Home
Search
Search Results
Previously Searched
3199 results found
Expand All
Apply All
3199 results found

Hill talks PAHPA and PBMs
Bio.News  •  July 14, 2023
A busy Thursday on Capitol Hill brought progress on PAHPA and questions about PBMs—here’s what happened. (646 words, 3 minutes, 13 seconds)
Read More

Gene-editing Technologies: Powerful Tools for Rewriting the Code of Life
Webinars  •  July 14, 2023
  The Cell and Gene Therapy (CGT) Science Series is a quarterly seminar series focused on scientific topics related to cell and gene therapy products. The CGT Science Series is intended to foster scientific exchange between the Biotechnology Innovation Organization (BIO), the American Society of Cell & Gene Therapy (ASGCT), and Center for Biologics Evaluation and Research (CBER) review staff on a variety of topics that span the CGT product lifecycle. The seminars are planned as 60-minute virtual webinars featuring a speaker from one of the three organizations. The CGT Science Series will enable a deep dive into a specific technical and/or scientific area. Topics in the series may include but are not limited to, nonclinical, CMC, clinical, or post-market phases of development related to CGT product lifecycle. Moderator: – Anne-Virginie Eggimann, Tessera Opening Remarks: – Cartier Esham, Senior Advisor, Biotechnology Innovation Organization (BIO) Speaker: – Jing Liao, Director, Vector Development and Operations, Alexion Pharmaceuticals
Read More
BTN-MTC_Researchers-DNA-364x210

Inquiry Form for Nikon
BIO Business Solutions
BIO Business Solutions® is the largest cost savings purchasing program for the biotech industry operated by the Biotechnology Innovation Organization (BIO). With more than half a billion in annual sales, BIO Business Solutions® aggregates the purchasing power of over 4,700 life science companies from North America. Companies of all sizes save substantial money each year through this cost-savings program. To request information for the BIO-Nikon Program, please fill the fields below and click the Submit button at the bottom of the form.   MktoForms2.loadForm("//app-ab15.marketo.com", "490-EHZ-999", 3881);
Read More

Congress continues its focus on PBMs
Bio.News  •  July 13, 2023
PBMs were on the agenda in the House and Senate yesterday—here’s what happened. Plus, as demand for protein grows, biotech is providing sustainable options. (646 words, 3 minutes, 13 seconds)
Read More

Coalition Letter Re PIPs Rule
Agriculture & Environment  •  Letters, Testimony & Comments  •  July 12, 2023
BIO and 59 other organizations have written to House and Senate Agriculture Committee leaders to ask that they direct Congress to withdraw the current rule concerning regulation of plant incorporated protectants and replace it one based on a science-based consideration of the risks and benefits of PIPs.
Read More

Inquiry Form for ShareVault
BIO Business Solutions
BIO Business Solutions® is the largest cost savings purchasing program for the biotech industry operated by the Biotechnology Innovation Organization (BIO). With more than half a billion in annual sales, BIO Business Solutions® aggregates the purchasing power of over 4,700 life science companies from North America. Companies of all sizes save substantial money each year through this cost-savings program. To request information for the BIO-ShareVault Program, please fill the fields below and click the Submit button at the bottom of the form.   MktoForms2.loadForm("//app-ab15.marketo.com", "490-EHZ-999", 3880);
Read More

AMR is a crisis ‘here and now’
Bio.News  •  July 12, 2023
A BIO witness explained to Senators why we need urgent Congressional action to fix the broken marketplace for antimicrobials—we have a recap, plus, how biotech can help tackle the growing number of heat-related deaths. (509 words, 2 minutes, 32 seconds)
Read More

PAHPA and Farm Bill priorities
Bio.News  •  July 11, 2023
BIO submitted comments on PAHPA reauthorization—here’s what we said. Plus, the Farm Bill expires in a few months, and we explain why it matters to biotech. (661 words, 3 minutes, 18 seconds)
Read More

BIO Comments to the Senate Committee on Health, Education, Labor and Pensions on the Reauthorization of PAHPA
Human Health  •  Letters, Testimony & Comments  •  July 10, 2023
BIO provides detailed comments to the Committee on its draft of the 2023 Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA), legislation that is critical to our national health security.
Read More

CMS price controls guidance and LEQEMBI
Bio.News  •  July 10, 2023
Congress is back—and so is Good Day BIO, with the biggest headlines from last week: CMS released revised guidance on the Inflation Reduction Act drug price controls, and FDA granted traditional approval to LEQEMBI. (689 words, 3 minutes, 26 seconds)
Read More